PEPTIDESTAT
ApprovedReproductive & hormoneSubcutaneousEvidence 4/5

Ganirelix

Also known as: Ganirelix acetate, Orgalutran, Antagon

Ganirelix competitively blocks GnRH receptors on pituitary gonadotrophs, producing rapid, reversible suppression of LH and FSH secretion without an initial stimulatory flare.

Read guideBuy / compare source
Ganirelix
Drug class
GnRH antagonist (synthetic decapeptide)
Primary targets
GnRH receptor, Pituitary gonadotroph, Luteinizing hormone (LH), Follicle-stimulating hormone (FSH)
Dose reference
Label dose of 0.25 mg subcutaneously once daily during the mid-to-late follicular phase until ovulation is triggered (a label figure, not a recommendation)
Half-life
About 12.8 hours after a single 0.25 mg dose; roughly 16.2 hours at steady state with daily dosing (label)
Developer / origin
N.V. Organon (Oss, the Netherlands)
Reference year
1999
Evidence score
4/5 - Approved, strong label and trial evidence within a narrow indication

Approved uses

  • Inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation as part of assisted reproductive technology (IVF)
Evidence 4/5

Approved, strong label and trial evidence within a narrow indication

Ganirelix is FDA-approved (1999) with prescribing-information-backed pharmacology and phase III trial evidence supporting GnRH-antagonist protocols for preventing premature LH surges in controlled ovarian stimulation, though evidence is confined to this single IVF-adjunct indication.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • FDA/DailyMed and Organon prescribing information document mechanism, pharmacokinetics (91% bioavailability, ~12.8 h half-life), 0.25 mg SC daily dosing and safety
  • Phase III Fertility and Sterility trial compared ganirelix vs leuprolide acetate in controlled ovarian hyperstimulation
  • Oberyé et al. phase I PK/PD studies established dose-proportional, rapidly reversible gonadotropin suppression
  • ClinicalTrials.gov registered comparative trials (e.g., NCT00298025 vs cetrorelix)

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Ganirelix guides

Read the matching guide or adjacent research pages for more context.

Ganirelix Peptide: GnRH Antagonist for IVF, Uses and SafetyGanirelix is an FDA-approved GnRH antagonist peptide used to block premature LH surges during controlled ovarian stimulation for IVF.Atosiban Peptide: Tractocile, Oxytocin Antagonist Tocolytic for Preterm LaborAtosiban is an EU-approved oxytocin and vasopressin receptor antagonist peptide used intravenously as a short-term tocolytic to delay preterm labor.Cetrorelix Peptide: Cetrotide, GnRH Antagonist Uses and SafetyCetrorelix is an FDA-approved GnRH antagonist peptide used in IVF to block premature LH surges without the early flare of GnRH agonists.Degarelix Peptide: Firmagon, GnRH Antagonist Uses and Safety LimitsDegarelix is an FDA-approved GnRH antagonist peptide that rapidly suppresses testosterone in advanced prostate cancer without the initial hormone flare seen with agonists.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Triptorelin

Trelstar, Decapeptyl

5/5
Reproductive & hormoneApproved

Triptorelin is a potent GnRH-receptor agonist that first transiently stimulates LH and FSH release, then, with continuous exposure, downregulates and desensitizes pituitary GnRH receptors to suppress gonadotropins and sex steroids.

DetailsGuide

Goserelin

Zoladex

5/5
Reproductive & hormoneApproved

Goserelin is a synthetic decapeptide GnRH agonist that first stimulates and then, with continuous depot exposure, downregulates pituitary GnRH receptors to suppress LH, FSH and downstream sex steroids toward castrate or postmenopausal levels.

DetailsGuide

Buserelin

Suprefact

4/5
Reproductive & hormoneApproved

Buserelin is a GnRH receptor superagonist that initially stimulates and then, with continuous non-pulsatile exposure, desensitizes pituitary gonadotrophs to suppress LH, FSH and downstream testosterone or estradiol production.

DetailsGuide

Nafarelin

Synarel

4/5
Reproductive & hormoneApproved

Nafarelin is a potent GnRH receptor agonist that initially stimulates pituitary LH and FSH release but with continued dosing downregulates the receptor, suppressing gonadotropins and sex steroid production.

DetailsGuide

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.